Science Hub is Novo Nordisk’s one-stop portal for all our scientific publications and clinical trials, congress materials and medical updates. Sign up to gain full access.
3-Month Real-World Weight Outcomes Among Patients With Overweight or Obesity After Switching From Injectable Semaglutide or Tirzepatide to Oral Semaglutide for Weight Management: The OCTANE Study
Sorry! It looks like the page you are trying to access contains materials that are still under embargo. Please come back and check again later.